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Abstract
Introduction: The UNAIDS 90-90-90 targets for the cascade of care are widely used to monitor the success of HIV care pro-
grammes but there are few studies in children. We assessed the cascade for children and adolescents living with HIV in the
national Collaborative HIV Paediatric Study (CHIPS) in the UK and Ireland.
Methods: Utilizing longitudinal data from CHIPS we compared the cascade of care for 2010, 2013 and 2016. Among children
diagnosed with HIV and not known to be lost to follow-up at the start of each calendar year, we summarized the proportion
in active paediatric care during that year (defined as having ≥1 clinic visit, CD4 or viral load measurement, or change to
antiretroviral therapy (ART) regimen), and of these, the proportion on ART at last visit in that year. Among those on ART, the
proportion with viral suppression (<200 copies/mL) and good immune status (WHO immunological stage none-/mild-for-age)
at last visit in the year were summarized. Among those in care in 2016, outcomes were compared by current age, place of
birth (born abroad vs. UK/Ireland) and sex.
Results: Of children in paediatric HIV care at the start of 2010, 2013 and 2016 (n = 1249, 1157, 905 respectively), the pro-
portion in active care during that calendar year was high throughout at 97 to 99%. Of those in active care, the proportion on
ART increased from 79% to 85% and 92% respectively (p < 0.001). Among those on ART, the proportion with viral suppres-
sion and good immune status was stable at 83% to 86% and 85% to 88%, respectively, across the years. Among children in
care in 2016, those aged ≥15 years were less likely to be virally suppressed (79% vs. 91%, p < 0.001) or to have good
immune status (78% vs. 94%, p < 0.001) compared to younger children; there were no differences by place of birth or sex.
Conclusions: Children and adolescents in the UK and Ireland national cohort had high retention in care. The proportion on
ART increased significantly over time although there was no change in viral suppression or good immune status. Poorer out-
comes among adolescents highlight the need for targeted support for this population.
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1 | INTRODUCTION
The HIV cascade of care is a model which outlines the steps
from HIV infection that individuals must pass through to
achieve viral suppression, with intermediate stages including
diagnosis, linkage to care and antiretroviral therapy (ART) initi-
ation, and is widely used to monitor the performance of HIV
healthcare systems [1-3]. In 2014 UNAIDS announced the
90-90-90 treatment targets, with the aim that by 2020, 90%
of people living with HIV should be diagnosed, 90% of those
diagnosed should be on treatment, and 90% of those on treat-
ment should be virally suppressed [4]. The cascade of care has
also been extended to stages including quality of life, immune
recovery, and other markers of well-being beyond just viral
suppression [5,6].
To date, the majority of studies describing the cascade of
care are among adults with HIV [1,6,7], with few studies in
children. The majority of those published focus on children
within the context of prevention of vertical transmission of
HIV [8-10], or on adolescents and young adults living with
HIV [11]. As children with vertically acquired HIV will require
lifelong treatment [12], maintaining long-term viral suppres-
sion on ART is a key challenge [13,14]. In this study, we uti-
lized longitudinal data from the national Collaborative HIV
Paediatric Study (CHIPS) in the UK and Ireland to assess the
cascade of care in children and adolescents in 2010, 2013
Chappell E et al. Journal of the International AIDS Society 2019, 22:e25379
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25379/full | https://doi.org/10.1002/jia2.25379
1
and 2016, following the recommendation of universal treat-
ment in 2016 [15].
2 | METHODS
All children aged <16 years diagnosed with HIV in the UK
and Ireland are reported to the National Study of HIV in
Pregnancy and Childhood (NSHPC) and have been followed
longitudinally in CHIPS since 2000 (with retrospective collec-
tion back to 1996) [16]. Data collected include ART, CD4 and
viral load (VL) measurements, and are pseudo-anonymized.
Both studies have NHS Research Ethics approval.
The cascade of care was assessed for three calendar years:
2010, 2013 and 2016. In adult cascade studies the first stage
is normally the estimated number of adults living with HIV
[17], but there are no equivalent data on the estimated num-
ber of children living with HIV in the UK/Ireland due to the
high proportion of children born abroad who migrated into
the country; our cascade therefore begins with the denomina-
tor of those diagnosed with HIV in the UK/Ireland. Children
were eligible for inclusion and defined as in care if, as of the 1
January of each calendar year of interest, they had been diag-
nosed with HIV, were aged <21 years and not known to have
died, left the country, or transferred to adult care, and had
not been lost-to-follow-up (LTFU) (defined as no visit in the
previous three years, or otherwise reported by their clinic). In
sensitivity analysis, all children ever LTFU were included in
the denominator until age 21, regardless of time since their
last visit.
Characteristics at the start of each year were described,
and the following cascade stages summarized: (i) the propor-
tion in active HIV care (defined as a clinic visit, CD4 or VL
measurement, or change to ART regimen) in that year; (ii) of
those in active HIV care, the proportion on ART at their last
visit in that year; (iii) of those on ART, the proportion virologi-
cally suppressed (with two thresholds used: VL <200 and
<50 copies/mL) at their last visit in that year. We added a
fourth cascade stage to indicate the immunological status of
patients: (iv) of those on ART, the proportion with good
immune status (defined as WHO immunological stage none-/
mild-for-age, corresponding to CD4 >30% for those aged
<1 year, CD4 >25% for those one to three years, CD4 >20%
for those three to five years, CD4 >350 cells/mm3 for those
≥5 years [18]) at their last visit in that year. Children with no
available VL/CD4 measurement during the year were consid-
ered to be unsuppressed/to have poor immune status, but in
a sensitivity analysis we included only those children with a
VL/CD4 measurement available. We also present the propor-
tion of the total cohort in care at the start of each year that
were virally suppressed and with good immune status at last
visit, irrespective of their retention or ART status.
Being on ART was defined as any ART regimen including
mono or dual therapy or combination ART (cART), with cART
defined as any regimen containing ≥3 drugs from ≥2 classes
(excluding 2 class regimens with an unboosted protease inhibi-
tor (PI)), or ≥3 nucleoside reverse transcriptase inhibitors
(NRTI) including abacavir.
Retention at each step of the cascade was compared over
the three calendar years using chi-squared tests. In addition,
in order to assess the most up-to-date cascade in more detail,
characteristics of those not on ART in 2016 were described,
and we stratified retention across the cascade for 2016 by
age at the start of the year (<5, 5 to <10, 10 to <15,
≥15 years), sex, and place of birth (born abroad vs. born in
the UK/Ireland).
All analyses were conducted using Stata version 15 (College
Station, TX, USA).
3 | RESULTS
Of children ever followed in CHIPS by the 1 January each
year, 1249/1781 (70%), 1157/1982 (58%) and 905/2095
(43%) met the inclusion criteria for the 2010, 2013 and 2016
analyses respectively (Table 1). The proportion eligible
decreased over time, mostly because of an increasing propor-
tion having transferred to adult care (17%, 28% and 42% in
2010, 2013 and 2016 respectively), which occurred at a med-
ian [interquartile range, IQR] 17.7 [16.8, 18.5] years of age.
There were three deaths between 2010 and 2012 among
children in care, and no deaths between 2013 and 2016.
Patient characteristics were broadly similar across calendar
years (Table 2). The vast majority (≥98% across all calendar
years) had acquired HIV vertically. Over time there was an
increase in the proportion of those born abroad diagnosed
prior to their arrival in the UK/Ireland (from 19% in 2010 to
28% in 2016, p = 0.001). Among those born abroad, the time
between arrival into the country and first HIV diagnosis was
relatively stable at around 0.5 years in each of the calendar
years. The median [IQR] age at start of each year increased
from 11.8 [8.5, 14.3] years in 2010 to 14.4 [11.2, 16.4] years
in 2016 (p < 0.001), and the median [IQR] age at ART initia-
tion decreased from 5.3 [1.6, 10.2] to 4.6 [1.0, 9.5] years
respectively (p = 0.035).
3.1 | Cascade of care over time
The proportion of children retained across each stage of the
cascade in each year is shown in Table 3. The proportion in
active care ranged between 97% and 99% across the three
calendar years (p = 0.004). Of those in active care, the pro-
portion on ART increased from 79% in 2010 to 85% in 2013
and 92% in 2016 (p < 0.001), corresponding to 76%, 84%
Table 1. Reason for exclusion from cascade analysis, by calendar
year
2010
(N = 1781)
2013
(N = 1982)
2016
(N = 2095)
Excluded from analysis 532 (30%) 825 (42%) 1190 (57%)
Died 111 (6%) 114 (6%) 114 (5%)
Moved abroad 69 (4%) 79 (4%) 84 (4%)
Transferred to adult care 297 (17%) 547 (28%) 884 (42%)
Lost-to-follow-up 40 (2%) 44 (2%) 34 (2%)
>21 years 15 (1%) 41 (2%) 74 (4%)
Included in analysis 1249 (70%) 1157 (58%) 905 (43%)
N refers to total number diagnosed in the UK/Ireland by the begin-
ning of each calendar year.
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and 90% of all those in care respectively. Among those on
treatment, the proportion virologically suppressed
<200 copies/mL and the proportion with good immune status
were relatively stable at between 83% to 86% (p = 0.163)
and 85% to 88% (p = 0.366) in the 3 years respectively,
although there was an increase in the proportion suppressed
<50 copies/mL from 72% to 79% and 77% respectively
(p = 0.003).
When considering the total cohort in care, the propor-
tion virologically suppressed <200 copies/mL increased
significantly from 64% in 2010 to 79% in 2016 (p < 0.001),
and the proportion with good immune status increased
slightly from 82% in 2010 to 86% in 2013 to 85% in 2016
(p = 0.020).
In the first sensitivity analysis, where we included children
LTFU, the proportion in active care decreased to 94%, 95%
and 94% in 2010, 2013 and 2016 respectively (data not
shown). In the second sensitivity analysis including only chil-
dren on ART with a VL/CD4 measurement available, the pro-
portions suppressed <200 copies/mL and with good immune
Table 2. Patient characteristics, by calendar year
2010 (N = 1249) 2013 (N = 1157) 2016 (N = 905)
p-valuen (%) or median [IQR]
Sex: female 645/1248 (52%) 604/1157 (52%) 483/902 (54%) 0.687
Place of birth: born abroad 638/1247 (51%) 613/1156 (53%) 471/904 (52%) 0.658
Previously diagnosed abroad 121/638 (19%) 139/613 (23%) 134/471 (28%) 0.001
Age at diagnosis among those born in the UK/Ireland,
years (n = 609, 543, 433)a
1.0 [0.3, 2.7] 0.9 [0.3, 2.7] 0.8 [0.3, 2.7] 0.875
Age at diagnosis in the UK/Ireland among those born
abroad, years (n = 638, 613, 471)a
6.8 [4.2, 9.7] 7.0 [4.2, 10.3] 6.5 [3.7, 9.9] 0.370
Time between arrival and first HIV diagnosis in the UK/Ireland
among those born abroad, years (n = 487, 455, 367)a
0.5 [0.1, 1.5] 0.4 [0.1, 1.5] 0.4 [0.1, 1.2] 0.789
Mode of infection: vertically acquired 1183/1203 (98%) 1097/1113 (99%) 867/880 (99%) 0.913
Ethnicity: black African 991/1237 (80%) 930/1148 (81%) 716/894 (80%) 0.736
Age at ART initiation, years 5.3 [1.6, 10.2] 5.2 [1.3, 10.2] 4.6 [1.0, 9.5] 0.035
Age at start of year, years 11.8 [8.5, 14.3] 13.2 [10.2, 15.6] 14.4 [11.2, 16.4] <0.001
Duration of follow-up in CHIPS, years 6.1 [3.2, 9.5] 7.6 [4.3, 11.0] 9.0 [5.5, 12.3] <0.001
ART, antiretroviral therapy.
an corresponds to the number with available date of diagnosis and/or date of arrival in the UK/Ireland.
Table 3. The cascade of care, by calendar year
2010 2013 2016
p-valuen (%)
In active care during year 1208/1249 (97%) 1142/1157 (99%) 886/905 (98%) 0.004
Among those in active care: on ART 953/1208 (79%) 975/1142 (85%) 819/886 (92%) <0.001
Among those on ART: virologically suppressed <200 copies/mL 793/953 (83%) 840/975 (86%) 701/819 (86%) 0.163
Among those on ART: virologically suppressed <50 copies/mL 688/953 (72%) 767/975 (79%) 632/819 (77%) 0.003
Among those on ART: good immune statusa 814/953 (85%) 854/975 (88%) 711/819 (87%) 0.366
Of total cohort: virologically suppressed <200 copies/mL 809/1249 (64%) 859/1157 (74%) 714/905 (79%) <0.001
Of total cohort: virologically suppressed <50 copies/mL 695/1249 (56%) 777/1157 (67%) 640/905 (71%) <0.001
Of total cohort: good immune statusa 1025/1249 (82%) 996/1157 (86%) 769/901 (85%) 0.020
Sensitivity analysis
Among those on ART with a VL available: virologically
suppressed <200 copies/mL
793/931 (85%) 840/943 (89%) 701/787 (89%) 0.014
Among those on ART with a VL available: virologically
suppressed <50 copies/mL
688/931 (74%) 767/943 (81%) 632/787 (80%) <0.001
Among those on ART with a CD4 available: good immune statusa 814/920 (88%) 854/942 (91%) 711/770 (92%) 0.026
ART, antiretroviral therapy; VL, viral load.
aGood immune status defined as WHO immunological stage none-/mild-for-age, corresponding to CD4 >30% for those aged <1 year, CD4 >25%
for those one to three years, CD4 >20% for those three to five years, CD4 >350 cells/mm3 for those ≥5 years.
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status both increased over time, from 85% to 89%
(p = 0.014) and 88% to 92% respectively (p = 0.026).
3.2 | Cascade of care in 2016
Among children in active care in 2016, 92% (819/886) were
on ART at their last visit in 2016, of whom 7% (60/819) were
on a non-cART regimen: 22 (37%) were on boosted PI
monotherapy, 15 (25%) were on a boosted PI and integrase
inhibitor, and 14 (23%) were on a boosted PI and 1 NRTI/
non-nucleoside reverse transcriptase inhibitor (NNRTI). Viral
suppression <200 copies/mL was higher among those on
cART (87%, 659/759) compared to those on non-cART regi-
mens (70%, 42/60) (p < 0.001).
Of the 67 (8%) children in active care but not on ART at last
visit in 2016, 24 (36%) had previously received ART but subse-
quently stopped for a median of 326 [110, 1224] days, with the
most common reason being adherence difficulties (n = 13,
54%). Among this group of patients subsequently off ART, the
median age at the beginning of 2016 was 15.7 [13.2, 18.0]
years. The median CD4 count among those aged ≥5 years
(n = 18/22 with a CD4 measurement available) was 409 [315,
611] cells/mm3; five had a CD4 count ≤350 cells/mm3 and one
had severe immunosuppression with CD4 ≤200 cells/mm3. Of
two children aged <5 years, one had a CD4% measurement
available of 46%. The remaining 43 (64%) were ART na€ıve, with
a median age at the beginning of 2016 of 12.5 [9.7, 14.8] years,
and of whom 20 (47%) were born abroad. The median CD4
count was 668 [575, 821] cells/mm3 among those aged
≥5 years (n = 33/41 with a CD4 measurement available), and
the two children aged <5 years had CD4% of 37% and 41%.
Forty (93%) of the ART-na€ıve group had CDC stage N or A clas-
sification, and 3 (7%) stage B.
The cascade of care by current age at start of 2016 is
shown in Figure 1. Compared to younger children aged
<15 years, those aged ≥15 years were less likely to be virally
suppressed <200 copies/mL (79% vs. 91%, p < 0.001) or have
good immune status (78% vs. 94%, p < 0.001), though there
was no significant difference in the proportion in active care
(p = 0.252) or on ART (p = 0.206). Similar trends were
observed in the cascade for 2010 and 2013 (data not shown).
A lower proportion of children born abroad had good immune
status (84% vs. 89%, p = 0.034), but there were no differ-
ences at other stages of the cascade of care, and there were
no differences by sex (data not shown).
4 | DISCUSSION
In our national cohort of children and adolescents with HIV,
the vast majority of whom acquired HIV vertically and had
been in care for several years, we observed high levels of
retention across the cascade in 2010, 2013 and 2016 and
there were no deaths among children in paediatric HIV care
between 2013 and 2016. This likely reflect the increase in the
proportion on ART over calendar time and a decrease in the
median age at initiation, consistent with treatment guideline
changes in 2016 to recommend universal ART [15]. While
retention across other stages remained stable, there was a
corresponding increase in the proportion of the total cohort
who were virally suppressed and with good immune status. By
2016, 90% of the cohort were on ART, of which 85% were
virologically suppressed, close to meeting the final two stages
of the 90-90-90 targets. Of those children not on treatment,
the majority were ART na€ıve with high CD4 counts and were
clinically well, although one-third had interrupted treatment.
The total number in paediatric care decreased over time, as
children aged and transferred to adult care.
Although there were no differences in retention in active
care and on treatment, adolescents in our cohort had poorer
outcomes on ART (viral suppression and good immune status)
compared to younger children. In 2017, the UK reported to
have met 90-90-90 target among adults aged ≥15 years [17];
although an age-disaggregated cascade was not provided, pre-
vious studies in the UK had reported poorer retention in the
cascade among 15 to 24 year olds compared to older age
groups [19]. A global meta-analysis also demonstrated poor
adherence among adolescents [20], and another UK study
from our group observed declining immunological outcomes
with age among adolescents [21]. This trend of poor outcomes
has been observed to continue in young adults with perinatal
HIV following transition to adult care, highlighting a key
98%
92%
86% 87%
100%
87%
96% 96%97% 91% 93% 90%
99%
92% 90% 95%
97% 94%
79% 78%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
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In acve care On ART VL≤200 copies/mL Good immune status
Overall (n = 905) <5 years (n = 30) 5–<10 years (n = 137) 10–<15 years (n = 331) ≥15 years (n = 407)
Figure 1. The cascade of care in 2016, overall and by age at start of 2016.
Proportion with VL<200 copies/mL and with good immune status are among all on ART, assuming those with no VL and CD4 measurement avail-
able, respectively, did not meet the outcome.
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population who may need additional support to achieve the
same level of cascade success [11,22].
There are very few published studies of the paediatric cas-
cade in high-income countries, and to our knowledge this is
one of the first comprehensive national assessments of the
cascade of care, including children and adolescents with HIV
across the UK and Ireland. One study of 525 children with
perinatal HIV aged <18 years across the Netherlands in 2016
reported very high success rates with 96% on treatment, of
whom 97% were virally suppressed ≤ 100 copies/mL [23]. A
study of 467 youth with horizontally acquired HIV aged 13 to
24 years in care across the USA during 2015 (of whom half
had been diagnosed for less than 3 years) found 86% were
engaged in care, of whom 98% were on ART, and of these
89% were suppressed <200 copies/mL [24]. The proportion
engaged in care in the USA study is substantially lower than
in our cohort, this is possibly due to the difference in mode of
infection and shorter duration since HIV diagnosis.
In our study we observed no effect of sex on the cascade.
Children who were born abroad had comparable retention to
those born in the UK/Ireland throughout the cascade, apart
from a lower proportion having good immune status. However,
it is important to note this is an unadjusted analysis, and that
children who were born abroad were older when diagnosed
with HIV and at ART start compared to UK and Ireland-born
children, which can limit the speed and extent of immune
recovery [25]. Our findings are consistent with a recent study
of children across Europe, which reported no effect of migrant
status in multivariable analyses on immune and virological out-
comes on ART [26].
This study has a number of limitations. First, without being
able to estimate the total number of children living with HIV in
the UK/Ireland we were unable to estimate the proportion who
had been diagnosed, corresponding to the first stage of the 90-
90-90 targets. Although we have full coverage of those born
with HIV in the UK, the number with HIV arriving in the UK or
Ireland from abroad is difficult to assess. However, given that
an increasing proportion of children born abroad were already
diagnosed prior to arrival in the UK or Ireland [27], and that the
median time between arrival and first HIV diagnosis in the UK
or Ireland was short at six months, it is likely that most children
living with HIV are captured. Second, we excluded those lost-to-
follow-up prior to each calendar year of interest from the
denominator of the cascade. However, a very conservative defi-
nition of loss-to-follow-up was used (not seen for >3 years, or
otherwise defined by their clinic), making the assumption that
those excluded were likely to have died or moved abroad, and
results from sensitivity analyses were similar. Third, most ado-
lescents with horizontally acquired HIV receive care in adult
services in the UK and would therefore not be captured here.
Finally, delay in reporting of data to CHIPS by clinics may have
resulted in some individuals being incorrectly classified as not in
active care.
5 | CONCLUSIONS
Children and adolescents in the UK and Ireland had high
retention in care throughout the calendar years assessed,
close to meeting the second and third stages of the 90-90-90
targets. Provision of ART increased significantly over recent
years although there was no change in the proportion with
viral suppression or good immune status. Poorer outcomes
among adolescents highlight the need for targeted support for
this population. The cascade is an important tool to give an
overview of the national picture, but more detailed study is
required to understand what can be done to address leaks
across all stages.
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